You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
太美醫療科技通過港交所聆訊,為中國最大醫藥及醫療器械研發數字化解決方案供應商
據港交所文件,9月16日晚,浙江太美醫療科技股份有限公司(簡稱“太美醫療科技”或“公司”)通過港交所聆訊。太美醫療科技是一家在中國專注於醫藥及醫療器械行業的數字化解決方案供應商,設計及提供行業特定的軟件及數字化服務,有助醫藥及醫療器械的研發、開發及營銷。根據灼識諮詢的資料,以2023年的收入計算,太美醫療科技是中國醫藥及醫療器械研發和營銷領域最大的數字化解決方案供應商。公司亦是中國最大的醫藥及醫療器械研發數字化解決方案供應商,2023年收入佔據8.2%的市場份額。截至2024年3月31日,公司已為1400多家醫藥企業及受託研究機構提供服務,覆蓋全球25大醫藥企業中的21家及中國醫藥創新企業100強中的90家。根據灼識諮詢的資料,按客户數量計,公司已成為中國醫藥及醫療器械研發和營銷領域應用最廣泛的數字化解決方案供應商。截至2024年3月31日,公司的在手訂單金額超過人民幣16億元,涉及軟件產品及數字化服務項目約3500個。公司近年業績持續增長,總收入由2021年的人民幣466.2百萬元增長17.8%至2022年的人民幣549.2百萬元,及增加4.4%至2023年的人民幣573.1百萬元,並由截至2023年3月31日止三個月的人民幣129.2百萬元進一步增加2.2%至截至2024年3月31日止三個月的人民幣132.1百萬元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account